XNAS · Biotechnology
Last stored close · Nov 9, 2026
Close · Nov 9, 2026
$65.03-0.63%
Model Target
—
not published for this name
Implied upside
—
vs the model target
Valuation methods
—
no method met the standard
TickerWhale Score
—
Not scored in the latest run — the model needs every factor family, and one was unavailable for this name.
Score components
TickerWhale View
No narrated read for this name yet — the deterministic factors still carry the analysis.
What helps
- Valuation
What to watch
- Technical
- Quality & growth
Quality & growth
30%48Moderate
- Revenue growth -42.8%
- EPS growth -103.4%
Valuation
25%57Positive
- P/E -155.9
- EV/Sales 5.5
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
Revenue growth (industry)Top 87%
Gross margin (industry)Top 30%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
36/100Weak
Weighted composite of momentum, trend, relative strength, oscillators, volatility, drawdown and liquidity — not yet ranked against the universe in this run · 25% of the TickerWhale Score
Classic chart indicators
Buy
3 buy · 1 sell · 4 neutral of 8 votes
TickerWhale reads PTCT's technical setup as weak at 36/100, not yet ranked against the universe in this run. Classic chart indicators lean buy — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
5 / 9constructive
- vs 200-day-7.6%
- vs 50-day+0.6%
Momentum
Mixed
- RSI (14)52 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength14· weak trend
- MACD (12,26,9)buy(histogram 0.620)
How the classic verdict is reached
Moving averages (9) agree on buy — 5 buy vs 3 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 1 sell · 4 neutral.
Result — 3 buy vs 1 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-09 · revised_latestValuation multiples
- P/E (TTM)-155.9 · TTM loss
- P/S (TTM)5.9
- P/B—
- EV/EBITDA—
- EV/Sales5.5
- PEG—
Profitability & returns
- Gross margin93.0%
- Net margin-3.8%
- ROE—
- Debt/Equity—
Growth
- Revenue growth (YoY)-42.8%
- EPS growth (YoY)-103.4%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $6.0B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target — Under Review
Our valuation methods do not currently agree closely enough for us to publish a single target for this company. We would rather say so than print a number we cannot stand behind. The TickerWhale Score still reflects quality, growth and momentum.
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PTCTCurrentPTC Therapeutics | — | 36 | -155.9 | — | — | 5.5 | $65.03 | -0.63% | -42.8% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 82 | 102.1 | — | 12.6 | 9.7 | $98.76 | +5.22% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.8 | — | 5.2 | 1.6 | $289.00 | +2.00% | +7.5% | ||
| EXELExelixis | 77 | 89 | 21.6 | — | 10.1 | 7.5 | $71.74 | +3.12% | +9.2% | ||
| TGTXTG Therapeutics | 77 | 85 | 22.6 | — | 16.5 | 12.8 | $63.38 | +5.94% | +76.1% | ||
| OSCROscar Health Inc - | 74 | 66 | 19.5 | — | 5.2 | 0.5 | $32.14 | +4.86% | +43.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.